Dental treatment for people with cystic fibrosis
- 652 Downloads
To describe the nature and consequences of the multi-system genetic condition cystic fibrosis with a view to ensuring optimal dental treatment planning for these patients.
A literature search was conducted to identify the key medical and dental manifestations of cystic fibrosis. These findings are discussed and utilised to create recommendations for treatment planning in patients with cystic fibrosis for the practising dental practitioner.
Cystic fibrosis is a complex, lethal, multisystem autosomal recessive disorder resulting from mutations on chromosome 7 which result in dysfunction of an ion channel that sits on epithelial surfaces. Respiratory disease remains the leading cause of mortality. Survival has greatly increased in recent decades secondary to improved treatment and specialist care. Specific dental manifestations of the disease may result from the condition itself or complications of treatment. Modification of patient management may be necessary to provide optimum patient care.
The pathophysiology and clinical manifestations are relevant to practicing dental practitioners and inform recommendations to be utilised to ensure optimal treatment planning for these patients.
KeywordsCystic fibrosis Caries Respiratory Dental
The authors would like to acknowledge the kind contribution of the clinical image by Dr. Rowland Bright-Thomas, Manchester Adult CF Centre.
Compliance with Ethical Standards
Conflict of interest
PB has received honoraria and financial support for educational activities from Vertex pharmaceuticals Ltd.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Azevedo TDPL, Feijó GCS, Bezerra ACB. Presence of developmental defects of enamel in cystic fibrosis patients. J Dent Child. 2006;73:159–63.Google Scholar
- Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2014. doi: 10.1002/14651858.CD001915.pub4.
- Brihaye P, Jorissen M, Clement PA. Chronic rhinosinusitis in cystic fibrosis (mucoviscidosis). Acta Otorhinolaryngol. 1997;51:323–37.Google Scholar
- Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2014. doi: 10.1002/14651858.CD002010.pub3.
- de Oliveira AC, Maluta RP, Stella AE, et al. Isolation of Pseudomonas aeruginosa strains from dental office environments and units in Barretos, state of São Paulo, Brazil, and analysis of their susceptibility to antimicrobial drugs. Braz J Microbiol. 2008;39:579–84.CrossRefPubMedPubMedCentralGoogle Scholar
- Mainz JG, Gerber A, Lorenz M, et al. Pseudomonas aeruginosa acquisition in cystic fibrosis patients in context of otorhinolaryngological surgery or dentist attendance: case series and discussion of preventive concepts. Case Rep Infect Dis. 2015. doi: 10.1155/2015/438517.
- Schuster A, Shwachman H. The tetracyclines; applied pharmacology. Pediatr Clin North Am. 1956;3:295–303.Google Scholar